Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Offers Guidance

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion.

Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Dare Bioscience (DARE) Tops Q2 EPS by 11c